Cytek Biosciences Inc (NAS:CTKB)
$ 3.4 -0.36 (-9.57%) Market Cap: 430.64 Mil Enterprise Value: 226.52 Mil PE Ratio: 0 PB Ratio: 1.14 GF Score: 70/100
Back to the Transcripts List

Q4 2024 Cytek Biosciences Inc Earnings Call Transcript

Feb 27, 2025 / 09:30 PM GMT
Release Date Price: $4.81 (-3.80%)

Key Points

Positve
  • Cytek Biosciences Inc (CTKB) achieved a 4% revenue growth in 2024, reaching $200.5 million, driven by strong service revenue and double-digit growth in international markets.
  • The company reported an 8.5% increase in unit volume growth for its full special profiling and imaging instruments, outperforming the broader flow cytometry market.
  • Cytek Biosciences Inc (CTKB) demonstrated a significant improvement in adjusted EBITDA, which increased by more than 77% from the previous year.
  • The company successfully repurchased 4 million shares in 2024 and announced a new $50 million repurchase program for 2025, reflecting strong cash flow and shareholder returns.
  • Cytek Biosciences Inc (CTKB) expanded its global footprint with a new manufacturing facility in Singapore, enhancing capacity and supply chain flexibility.
Negative
  • Total revenue for the fourth quarter of 2024 was flat compared to the previous year, with a 1% decrease due to a decline in product revenue and a strong US dollar.
  • US and EEA revenues declined by 10% and 18% respectively, driven by lower instrument sales and foreign exchange effects.
  • The company faces potential headwinds from new export controls, tariffs, and NIH funding reductions, which could impact future revenues.
  • Research and development expenses decreased by 11% in the fourth quarter, reflecting reduced compensation and engineering expenses, which may impact future innovation.
  • The company reported a GAAP net loss of $6 million for the year, primarily due to foreign exchange losses and lower tax benefits.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CTKB.OQ - Cytek Biosciences Inc
Q4 2024 Cytek Biosciences Inc Earnings Call
Feb 27, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by and good day everyone. My name is RJ and I will be your conference operator today. At this time, I would like to welcome everyone to the Side Bio Sciences 4th quarter and full year 2024 earnings conference call. All lines have been placed. On mute to prevent any background noise after the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question press star one again.

Thank you.

I would now like to turn the call over to Paul Goodson, head of investor relations. Please go ahead.

-------------------------------
Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.